Advanced Development of Inhibitors of human Lactate Dehydrogenase A (LDHA) as Anticancer Agents (Chemical Biology Consortium/NCI Experimental Therapeutics Collaboration)
$127,680ZIAFY2018TRNIH
National Center For Advancing Translational Sciences
Investigators
Linked publications & trials
Abstract
This collaborative team - composed of groups from NCI, CBC/NExT, U Penn, Vanderbilt, UAB, UNM and NCATS - aims to build on previous research by uncovering novel inhibitors of LDHA for anticancer indications. During this period, the NCATS group, as part of the LDHA collaborative team, has worked to characterize the mechanism of action of the novel LDH inhibitors, guide in vivo efficacy model development, assess in vitro activity of novel LDH degraders, and assess in vitro activity of novel tumor concentrating LDH inhibitors.
View original record on NIH RePORTER →